Optimizing management of sentinel lymph node limited residual tumor after neoadjuvant therapy for breast cancer: Balancing of act.
作者信息
Sun Jing, Shi Zhiqiang, Bi Zhao, Qiu Pengfei
机构信息
Breast Cancer Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China.
出版信息
Chin J Cancer Res. 2025 Apr 30;37(2):293-295. doi: 10.21147/j.issn.1000-9604.2025.02.13.
Abstract
摘要
相似文献
1
Optimizing management of sentinel lymph node limited residual tumor after neoadjuvant therapy for breast cancer: Balancing of act.优化乳腺癌新辅助治疗后前哨淋巴结微小残留肿瘤的管理：行动的平衡
Chin J Cancer Res. 2025 Apr 30;37(2):293-295. doi: 10.21147/j.issn.1000-9604.2025.02.13.
2
Sentinel lymph node biopsy performed after neoadjuvant chemotherapy is accurate in patients with documented node-positive breast cancer at presentation.对于初诊时记录为淋巴结阳性的乳腺癌患者，新辅助化疗后进行前哨淋巴结活检是准确的。
Ann Surg Oncol. 2007 Oct;14(10):2946-52. doi: 10.1245/s10434-007-9403-y. Epub 2007 May 19.
3
[Sentinel lymph node biopsy and neoadjuvant treatment in breast cancer].[乳腺癌前哨淋巴结活检与新辅助治疗]
Bull Cancer. 2017 Oct;104(10):892-901. doi: 10.1016/j.bulcan.2017.08.003. Epub 2017 Sep 8.
4
Intraoperative Assessment of Sentinel Lymph Nodes in Breast Cancer Patients Post-Neoadjuvant Therapy.新辅助治疗后乳腺癌患者前哨淋巴结的术中评估。
Technol Cancer Res Treat. 2019 Jan 1;18:1533033818821104. doi: 10.1177/1533033818821104.
5
Intraoperative sentinel lymph node evaluation in patients with node-positive breast cancer status post neoadjuvant systemic therapy - An institutional experience.新辅助全身治疗后淋巴结阳性乳腺癌患者的术中前哨淋巴结评估-机构经验。
Ann Diagn Pathol. 2022 Oct;60:152012. doi: 10.1016/j.anndiagpath.2022.152012. Epub 2022 Jul 22.
6
Prediction of non-sentinel lymph node metastases in T1-2 sentinel lymph node-positive breast cancer patients undergoing mastectomy following neoadjuvant therapy.新辅助治疗后行乳房切除术的 T1-2 前哨淋巴结阳性乳腺癌患者中非前哨淋巴结转移的预测。
World J Surg Oncol. 2024 Sep 28;22(1):258. doi: 10.1186/s12957-024-03537-9.
7
Update on sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patient.新辅助化疗后乳腺癌前哨淋巴结活检的最新进展。
Ann Ital Chir. 2020;91:465-468.
8
Selective Extirpation of Tattooed Lymph Node in Combination with Sentinel Lymph Node Biopsy in the Management of Node-Positive Breast Cancer Patients after Neoadjuvant Systemic Therapy.新辅助全身治疗后，对淋巴结阳性乳腺癌患者采用纹身淋巴结选择性切除联合前哨淋巴结活检的治疗方法。
Breast Care (Basel). 2021 Dec;16(6):623-629. doi: 10.1159/000514266. Epub 2021 Feb 17.
9
A comparison of sentinel node biopsy before and after neoadjuvant chemotherapy: timing is important.新辅助化疗前后前哨淋巴结活检的比较：时机很重要。
Am J Surg. 2005 Oct;190(4):517-20. doi: 10.1016/j.amjsurg.2005.06.004.
10
Accuracy and Limitations of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients with Positive Nodes.新辅助化疗后前哨淋巴结活检在阳性淋巴结乳腺癌患者中的准确性和局限性。
Breast J. 2022 Aug 5;2022:1507881. doi: 10.1155/2022/1507881. eCollection 2022.
本文引用的文献
1
Nodal Burden and Oncologic Outcomes in Patients With Residual Isolated Tumor Cells After Neoadjuvant Chemotherapy (ypN0i+): The OPBC-05/ICARO Study.新辅助化疗后残留孤立肿瘤细胞患者（ypN0i+）的淋巴结负荷与肿瘤学结局：OPBC-05/ICARO研究
J Clin Oncol. 2025 Mar;43(7):810-820. doi: 10.1200/JCO.24.01052. Epub 2024 Nov 7.
2
Advances in regional nodal management of early-stage breast cancer.早期乳腺癌区域淋巴结管理的进展
Chin J Cancer Res. 2024 Apr 30;36(2):215-225. doi: 10.21147/j.issn.1000-9604.2024.02.08.
3
Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023.了解乳腺癌的复杂性以改善患者结局：2023 年圣加仑国际乳腺癌早期个体化治疗共识会议。
Ann Oncol. 2023 Nov;34(11):970-986. doi: 10.1016/j.annonc.2023.08.017. Epub 2023 Sep 6.
4
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.阿贝西利联合内分泌治疗激素受体阳性、HER2 阴性、淋巴结阳性、高危早期乳腺癌（monarchE）：一项随机、开放标签、III 期临床试验的预先计划的中期分析结果。
Lancet Oncol. 2023 Jan;24(1):77-90. doi: 10.1016/S1470-2045(22)00694-5. Epub 2022 Dec 6.
5
De-escalation of radiotherapy after primary chemotherapy in cT1-2N1 breast cancer (RAPCHEM; BOOG 2010-03): 5-year follow-up results of a Dutch, prospective, registry study.cT1-2N1期乳腺癌新辅助化疗后放疗降阶梯治疗（RAPCHEM；BOOG 2010-03）：一项荷兰前瞻性注册研究的5年随访结果
Lancet Oncol. 2022 Sep;23(9):1201-1210. doi: 10.1016/S1470-2045(22)00482-X. Epub 2022 Aug 8.
6
Diagnostic Accuracy of Different Surgical Procedures for Axillary Staging After Neoadjuvant Systemic Therapy in Node-positive Breast Cancer: A Systematic Review and Meta-analysis.新辅助全身治疗后腋窝淋巴结阳性乳腺癌不同外科手术方法进行腋窝分期的诊断准确性：系统评价和荟萃分析。
Ann Surg. 2019 Mar;269(3):432-442. doi: 10.1097/SLA.0000000000003075.
7
Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection?新辅助化疗后前哨淋巴结低容量疾病是否需要腋窝清扫？
Ann Surg Oncol. 2018 Jun;25(6):1488-1494. doi: 10.1245/s10434-018-6429-2. Epub 2018 Mar 23.
8
Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.乳腺癌——美国癌症联合委员会第八版癌症分期手册的重大变化。
CA Cancer J Clin. 2017 Jul 8;67(4):290-303. doi: 10.3322/caac.21393. Epub 2017 Mar 14.
Zotero 插件